XXIV Cycle de Conférences

9 May 2018 – Théâtre Lúcio Costa –   20h30

A novel therapeutic strategy for skin allergic inflammation

Doumet G. HELOU – 3rd year PhD student at INSERM UMR 996, Université Paris-Sud, Faculté de Pharmacie, Châtenay-Malabry, France

Skin is the largest physical and immune barrier that could be directly exposed to many aggressions such as ultraviolet radiation, medication use and several chemical compounds. Allergic contact dermatitis is a major public health concern mainly provoked by skin exposure to low-molecular weight chemicals. This study evidence that the transcription factor Nrf2 (NF-E2-related factor-2) down regulates skin allergic inflammation in response to strong chemical sensitizers, through the control of different innate immune cells activation. Thus; we suggest that Nrf2 may be a therapeutic target for the control of exacerbated or/and chronic skin inflammation.

Impact of HIV infection on priming of antigen specific CD8+ T cell responses

Mariela PIRES CABRAL PICCIN – Postdoctoral Researcher at Centre d’Immunologie et Maladies Infectieuses – CIMI Paris – L’hôpital de la Pitié-Salpêtrière (Université Pierre et Marie Curie). PhD in Immunology (Federal University of Rio de Janeiro). Master’s degree in Infectious Diseases (Federal University of Espírito Santo). Bachelor of Pharmacy / Biochemistry (Federal University of Espírito Santo).

The key role of CD8 + T-cells in controlling HIV replication has been particularly well established. Functional and metabolic properties of HIV specific CD8 + T cells appear to be essential for an effective control of the virus, as shown in HIV-1 and HIV-2 controllers. Mounting of functional CD8 + T cell responses is dependent on the effective priming of antigen specific naïve CD8 + T-cells by professional antigen presenting cells. However, factors that may dampen or promote effective priming of CD8 + T-cell responses during HIV infection remain largely unknown. So, the aim of this study  is to provide further understanding of the CD8 + T cell efficacy against HIV by focusing on the initial step of the immune response, that is the priming of antigen specific naïve CD8 + T cells in individuals infected with HIV, and to investigate potential factors that may help us improving the induction of robust T cells.